A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00144495

Enrollment

104

Registered

2005-09-05

Start date

2004-02-29

Completion date

2005-05-31

Last updated

2009-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Induced Anemia

Brief summary

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

Interventions

DRUGrecombinant human erythropoietin

3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 79 Years

Healthy volunteers

Inclusion criteria

* Cancer patients

Exclusion criteria

* a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs

Design outcomes

Primary

Measure	Time frame
The increase in Hb concentration	Day 28th or later

Secondary

Measure	Time frame
Changes in QOL scores	84 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026